AU2008317331B2 - Antibody-mediated disruption of quorum sensing in bacteria - Google Patents

Antibody-mediated disruption of quorum sensing in bacteria Download PDF

Info

Publication number
AU2008317331B2
AU2008317331B2 AU2008317331A AU2008317331A AU2008317331B2 AU 2008317331 B2 AU2008317331 B2 AU 2008317331B2 AU 2008317331 A AU2008317331 A AU 2008317331A AU 2008317331 A AU2008317331 A AU 2008317331A AU 2008317331 B2 AU2008317331 B2 AU 2008317331B2
Authority
AU
Australia
Prior art keywords
seq
mammal
antibody
aureus
molecular entity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008317331A
Other languages
English (en)
Other versions
AU2008317331A1 (en
Inventor
Kim D. Janda
Gunnar F. Kaufmann
Junguk Park
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of AU2008317331A1 publication Critical patent/AU2008317331A1/en
Application granted granted Critical
Publication of AU2008317331B2 publication Critical patent/AU2008317331B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2008317331A 2007-10-25 2008-10-24 Antibody-mediated disruption of quorum sensing in bacteria Ceased AU2008317331B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98259307P 2007-10-25 2007-10-25
US60/982,593 2007-10-25
PCT/US2008/012151 WO2009055054A2 (en) 2007-10-25 2008-10-24 Antibody-mediated disruption of quorum sensing in bacteria

Publications (2)

Publication Number Publication Date
AU2008317331A1 AU2008317331A1 (en) 2009-04-30
AU2008317331B2 true AU2008317331B2 (en) 2013-08-29

Family

ID=40580303

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008317331A Ceased AU2008317331B2 (en) 2007-10-25 2008-10-24 Antibody-mediated disruption of quorum sensing in bacteria

Country Status (9)

Country Link
US (2) US9394371B2 (cg-RX-API-DMAC10.html)
EP (2) EP2842565B1 (cg-RX-API-DMAC10.html)
JP (3) JP5581490B2 (cg-RX-API-DMAC10.html)
KR (1) KR101557173B1 (cg-RX-API-DMAC10.html)
CN (2) CN104211775A (cg-RX-API-DMAC10.html)
AU (1) AU2008317331B2 (cg-RX-API-DMAC10.html)
CA (2) CA2975568A1 (cg-RX-API-DMAC10.html)
ES (1) ES2603061T3 (cg-RX-API-DMAC10.html)
WO (1) WO2009055054A2 (cg-RX-API-DMAC10.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6445442B2 (ja) 2012-10-26 2018-12-26 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ａｉｐ２を結合する抗感染症結合タンパク質
DE102013211850A1 (de) * 2013-06-21 2014-12-24 Gilupi Gmbh Schnelltest zum Nachweisen von Erregermaterial, insbesondere zur Unterstützung der Diagnose einer Sepsis, sowie Kit und Vorrichtung zur Durchführung eines Sepsistests
AU2014298373B2 (en) * 2013-08-01 2019-12-05 Ludwig Institute For Cancer Research Ltd Anti-GARP protein and uses thereof
JP2017509587A (ja) 2013-12-27 2017-04-06 ノーバス・インターナショナル・インコーポレイテッドＮｏｖｕｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ，Ｉｎｃ． エトキシル化界面活性剤
JP6517156B2 (ja) * 2014-01-29 2019-05-22 Ｋｍバイオロジクス株式会社 抗トランスサイレチンヒト抗体
CN106574258B (zh) 2014-01-29 2021-03-30 Km生物医药股份公司 抗-运甲状腺素蛋白人源化抗体
EP3103808B1 (en) 2014-02-07 2018-08-22 Miyarisan Pharmaceutical Co., Ltd. Peptide having activity of inhibiting production of toxin by bacterium belonging to genus clostridium
WO2017136400A1 (en) * 2016-02-02 2017-08-10 Stc. Unm Vlp-based vaccines for targeting staphylococcus aureus secreted virulence factors
US12662513B2 (en) * 2016-05-01 2026-06-23 Wisconsin Alumni Research Foundation Peptidic modulators of quorum sensing in Staphylococcus epidermidis
US10808010B2 (en) 2016-08-11 2020-10-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptide inhibitors of phosphoglycerate mutase and methods of use
US10836810B2 (en) 2017-02-17 2020-11-17 Mapp Biopharmaceutical, Inc. Monoclonal antibodies and cocktails for treatment of ebola infections
US10584306B2 (en) 2017-08-11 2020-03-10 Board Of Regents Of The University Of Oklahoma Surfactant microemulsions
US20210177917A1 (en) * 2017-08-31 2021-06-17 The Regents Of The University Of California Molecular bacteriotherapy to control skin enzymatic activity
JP7035170B2 (ja) 2017-09-15 2022-03-14 レンティジェン・テクノロジー・インコーポレイテッド 抗ｃｄ１９免疫療法によりがんを処置するための組成物および方法
US10774135B2 (en) 2017-12-22 2020-09-15 Sorrento Therapeutics, Inc. Variant antibodies that bind AIP2
JP7290146B2 (ja) 2018-02-13 2023-06-13 住友化学株式会社 組成物および成形体
EP4013372A4 (en) 2019-08-13 2023-08-30 McCord, Darlene E. Non-activated, amorphous, ph neutral, two-part bedside-ready clay delivery system that treats pathogen infections in humans and animals
CN111573853B (zh) * 2020-05-29 2020-11-20 南京大学 一种削减生物法处理废水毒性的方法
WO2023076855A1 (en) 2021-10-25 2023-05-04 Mccord Darlene E Coated medicinal clay compositions, pharmaceutical compositions, and delivery of cation sources and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004014423A1 (en) * 2002-08-13 2004-02-19 Haptogen Ltd Methods for the treatment of an infectious bacterial disease with an anti-lactone or lactone derived signal molecules antibody

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997044349A1 (en) * 1996-05-22 1997-11-27 New York University BLOCKING EXPRESSION OF VIRULENCE FACTORS IN $i(S. AUREUS)
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
US6559176B1 (en) * 2000-05-10 2003-05-06 Princeton University Compounds and methods for regulating bacterial growth and pathogenesis
US7786257B2 (en) * 2000-12-18 2010-08-31 University Of Kansas Signal-1/signal-2 bifunctional peptide inhibitors
US6463632B2 (en) * 2001-02-07 2002-10-15 Hans Oetiker Ag Maschinen-Und Apparatefabrik Guide arrangement for tightening tool emplacement in hose clamps provided with plastically deformable ears
CN1164612C (zh) * 2001-09-11 2004-09-01 四川新泰克控股有限责任公司 人工组合的抗菌工程多肽及其制备方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004014423A1 (en) * 2002-08-13 2004-02-19 Haptogen Ltd Methods for the treatment of an infectious bacterial disease with an anti-lactone or lactone derived signal molecules antibody

Also Published As

Publication number Publication date
KR101557173B1 (ko) 2015-10-05
US9394371B2 (en) 2016-07-19
WO2009055054A2 (en) 2009-04-30
EP2211889A2 (en) 2010-08-04
ES2603061T3 (es) 2017-02-23
JP2011500814A (ja) 2011-01-06
JP6183910B2 (ja) 2017-08-23
CA2703133C (en) 2017-09-19
KR20100102100A (ko) 2010-09-20
EP2842565A1 (en) 2015-03-04
WO2009055054A3 (en) 2009-09-03
EP2211889B1 (en) 2014-08-20
JP2014221774A (ja) 2014-11-27
US20100291093A1 (en) 2010-11-18
US20170043020A1 (en) 2017-02-16
JP2018021021A (ja) 2018-02-08
CN101835484B (zh) 2014-07-16
CN101835484A (zh) 2010-09-15
JP5581490B2 (ja) 2014-09-03
CA2703133A1 (en) 2009-04-30
AU2008317331A1 (en) 2009-04-30
CA2975568A1 (en) 2009-04-30
EP2211889A4 (en) 2012-01-11
CN104211775A (zh) 2014-12-17
EP2842565B1 (en) 2016-08-24

Similar Documents

Publication Publication Date Title
AU2008317331A1 (en) Antibody-mediated disruption of quorum sensing in bacteria
EP0937140B1 (en) Antibody molecules which interact specifically with the active site or cleft of a target molecule
ES2398693T3 (es) Métodos para el tratamiento de la artritis reumatoide
WO1997049805A9 (en) Recognition molecules interacting specifically with the active site or cleft of a target molecule
JP7525471B2 (ja) Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）クランピング因子Ａ（ＣｌｆＡ）に対する抗体
ES2669984T3 (es) Antagonistas de IL17C para el tratamiento de trastornos inflamatorios
US7658925B2 (en) Human anthrax toxin neutralizing monoclonal antibodies and methods of use thereof
JP6371758B2 (ja) 抗ブドウ球菌抗体、その製造方法並びにその使用
US20100003263A1 (en) Monoclonal antibodies to anthrax protective antigen
JP6556758B2 (ja) 黄色ブドウ球菌特異的抗体、それを用いた治療方法及び検出方法
US20040248201A1 (en) Recognition molecules interacting specifically with the active site or cleft of a target molecule

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired